Reactive astrocytes acquire neuroprotective as well as deleterious signatures in response to Tau and Aß pathology
Zoeb Jiwaji,Sachin S. Tiwari,Rolando X. Avilés-Reyes,Monique Hooley,David Hampton,Megan Torvell,Delinda A. Johnson,Jamie McQueen,Paul Baxter,Kayalvizhi Sabari-Sankar,Jing Qiu,Xin He,Jill Fowler,James Febery,Jenna Gregory,Jamie Rose,Jane Tulloch,Jamie Loan,David Story,Karina McDade,Amy M. Smith,Peta Greer,Matthew Ball,Peter C. Kind,Paul M. Matthews,Colin Smith,Owen Dando,Tara L. Spires-Jones,Jeffrey A. Johnson,Siddharthan Chandran,Giles E. Hardingham
DOI: https://doi.org/10.1038/s41467-021-27702-w
IF: 16.6
2022-01-10
Nature Communications
Abstract:Abstract Alzheimer’s disease (AD) alters astrocytes, but the effect of Aß and Tau pathology is poorly understood. TRAP-seq translatome analysis of astrocytes in APP/PS1 ß-amyloidopathy and MAPT P301S tauopathy mice revealed that only Aß influenced expression of AD risk genes, but both pathologies precociously induced age-dependent changes, and had distinct but overlapping signatures found in human post-mortem AD astrocytes. Both Aß and Tau pathology induced an astrocyte signature involving repression of bioenergetic and translation machinery, and induction of inflammation pathways plus protein degradation/proteostasis genes, the latter enriched in targets of inflammatory mediator Spi1 and stress-activated cytoprotective Nrf2. Astrocyte-specific Nrf2 expression induced a reactive phenotype which recapitulated elements of this proteostasis signature, reduced Aß deposition and phospho-tau accumulation in their respective models, and rescued brain-wide transcriptional deregulation, cellular pathology, neurodegeneration and behavioural/cognitive deficits. Thus, Aß and Tau induce overlapping astrocyte profiles associated with both deleterious and adaptive-protective signals, the latter of which can slow patho-progression.
multidisciplinary sciences